Ask AI
ALNEO
ALNEO: Phase II Trial of Perioperative Alectinib in Potentially Resectable Stage III ALK-Positive NSCLC

Released: June 04, 2025

Expiration: December 03, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: June 04, 2025

Expiration: December 03, 2025